Month: July 2017

Intact Vascular Announces Enrollment of First European Patient in Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial with the Tack Endovascular System®

July 18, 2017 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial has commenced enrollment in Europe, with the first patient treated by Professor Dr. Marianne Brodmann and Dr. Peter …

Intact Vascular Announces Enrollment of First European Patient in Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial with the Tack Endovascular System® Read More »

FDA Approves 6-Month Primary Endpoint for the Tack Endovascular System® in Below the Knee Disease

July 10, 2017 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) …

FDA Approves 6-Month Primary Endpoint for the Tack Endovascular System® in Below the Knee Disease Read More »

Scroll to Top
Intact Vascular uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this.